


Suven secures patents in 4 countries

20 February 2015 | News | By BioSpectrum Bureau

Suven secures patents in 4 countries



These patents are said to be valid until 2030.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

Histaminargic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders such as Alzheimer's, ADHD, dementia, depression, Huntington's disease and Parkinson's disease.

H3 receptor blockade elevates acetylcholine in brain regions responsible for cognition, thus offer a means for targeting cognitive processes.

Novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for this unmet medical need.

With these new patents, Suven has a total of twenty granted patents from Australia, seventeen from Canada, fifteen from Japan and twenty two from New Zealand.

These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

Products out of these inventions may be out-licensed at various phases of clinical development like at phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," said Mr Venkat Jasti,

CEO, Suven.